Mesoblast (NASDAQ:MESO) Sees Large Volume Increase – What’s Next?

Shares of Mesoblast Limited (NASDAQ:MESO) saw an uptick in trading volume on Thursday . Approximately 130,848 shares traded hands during trading, a decline of 43% from the previous session’s volume of 227,658 shares.The stock last traded at $19.0650 and had previously closed at $18.24.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Mesoblast in a research note on Tuesday, April 21st. One analyst has rated the stock with a Strong Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy”.

Mesoblast Price Performance

The company has a market cap of $2.24 billion, a PE ratio of -61.86 and a beta of 2.08. The firm’s 50-day moving average is $14.79 and its 200-day moving average is $15.81. The company has a quick ratio of 1.41, a current ratio of 1.58 and a debt-to-equity ratio of 0.10.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Rialto Wealth Management LLC purchased a new stake in shares of Mesoblast in the fourth quarter worth $839,000. Bank of America Corp DE lifted its position in shares of Mesoblast by 608.4% in the first quarter. Bank of America Corp DE now owns 100,004 shares of the company’s stock worth $1,538,000 after buying an additional 85,888 shares in the last quarter. Royal Bank of Canada boosted its position in shares of Mesoblast by 22.5% during the 1st quarter. Royal Bank of Canada now owns 26,266 shares of the company’s stock valued at $404,000 after acquiring an additional 4,827 shares during the last quarter. Caitong International Asset Management Co. Ltd purchased a new position in shares of Mesoblast in the 4th quarter worth $32,000. Finally, Tobias Financial Advisors Inc. grew its position in Mesoblast by 38.3% in the fourth quarter. Tobias Financial Advisors Inc. now owns 13,828 shares of the company’s stock worth $249,000 after acquiring an additional 3,828 shares in the last quarter. Institutional investors own 1.43% of the company’s stock.

About Mesoblast

Mesoblast Limited is a global leader in allogeneic cellular medicines, focused on developing treatments for inflammatory and immunologic diseases. Founded in 2004 by Dr. Silviu Itescu, the company builds on proprietary mesenchymal lineage cell technology to create off-the-shelf, donor-derived therapies. These therapies are designed to modulate immune responses and promote tissue repair in conditions where existing medical options are limited or ineffective.

The company’s most advanced product, Alofisel® (darvadstrocel), has been approved in Europe for the treatment of complex perianal fistulas in adults with Crohn’s disease.